Through the efforts of its working group on pricing and funding, AAMRNet has developed the ‘AAMRNet Position Statement: Pricing and reimbursement of novel antimicrobials in Australia‘, highlighting innovative strategies for bringing new antibiotic treatments to market.
The statement, released in May 2022, is aimed at stimulating discussion and spurring action.
It canvases ways to stimulate research and development for new treatments, novel reimbursement approaches to support and ensure a continuing pipeline of novel therapies and the merits of a pilot Australian fund to provide access to new antimicrobials and support their appropriate use